GlassScriptPhysician profile
Tiffany Lack
NPI 1700431723
$3,296.26
in general payments reported to CMS, 2019-2025
28 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $292 · 2022: $703 · 2023: $350 · 2024: $924 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,301.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $650.96 | 2023-2025 | |
| Axsome Therapeutics, INC. | $297.46 | 2024-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $288.80 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $211.66 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $204.38 | 2023-2025 | Fasenra, Airsupra, Farxiga |
| Abiomed | $185.24 | 2022-2023 | Impella |
| Novo Nordisk INC | $162.05 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $145.13 | 2025 | Qelbree |
| Scynexis, INC. | $140.15 | 2022 | |
| Bioventus LLC | $136.39 | 2022 | |
| Eisai INC. | $124.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.94 | 2021 | |
| Alkermes, INC. | $94.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $94.04 | 2022 | |
| Grt US Holding, INC. | $75.43 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $63.45 | 2024 | |
| Lundbeck LLC | $50.70 | 2024-2025 | Vyepti |
| Averitas Pharma INC. | $41.79 | 2023 | Qutenza |
| Dexcom, INC. | $28.43 | 2024 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.26 | 2025 | Caplyta |
| Medtronic, INC. | $26.25 | 2024 | Solitaire X |
| Shield Therapeutics INC | $25.46 | 2025 | |
| Boston Scientific Corporation | $23.03 | 2024 | Watchman Access System |
| Exact Sciences Corporation | $22.12 | 2024 | Cologuard Collection Kit |
| Organon LLC | $18.80 | 2025 | Nexplanon |
| Phadia US INC. | $16.01 | 2024 | Immunocap |
| Janssen Pharmaceuticals, INC | $15.85 | 2025 | Spravato |
| Pfizer INC. | $15.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Lack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.